Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Capmatinib · 1 trial · 1 indication
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.
The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, hematologic toxicity, pulmonary toxicity, liver enzyme elevation, or treatment delay greater than (\>) 28 days due to unresolved toxicity.
ORR is defined as the percentage of participants who achieve either a confirmed partial response (PR) or complete response (CR), using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
| Arm | Type | Description |
|---|---|---|
| Phase 1 (Combination Dose Selection) | EXPERIMENTAL | Participants will receive capmatinib 400 milligrams (mg) orally twice daily from Cycle 1 Day 1, in combination with amivantamab 700 mg intravenous (IV) infusion (for body weight less than 80 kilograms \[kg\]) or 1050 mg IV infusion (for body weight greater than or equal to 80 kg) once weekly from Cycle 1 Day 1 for 4 weeks and then every 2 weeks from Week 5 (Cycle 2; each cycle of 28 days). Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined by the study evaluation team (SET). |
| Phase 2 (Dose Expansion) | EXPERIMENTAL | Participants with mesenchymal-epithelial transition (MET) exon 14 skipping mutation who are treatment naïve (Cohort 1A), who have received prior therapy (Cohort 1B), or participants with MET amplification who have received prior therapy (Cohort 1C) will receive capmatinib in combination with amivantamab at the RP2CD determined by the SET in Phase 1. |
| Name | Type | Description |
|---|---|---|
| Capmatinib | DRUG | Capmatinib will be administered orally. |
| Amivantamab | DRUG | Amivantamab will be administered as IV infusion. |
Inclusion Criteria: * Previously diagnosed with histologically or cytologically confirmed unresectable Stage IV (metastatic) non-small cell lung cancer (NSCLC) (any histology) * May have: definitively, locally treated brain metastases that are clinically stable and asymptomatic for greater than (\>...
Capmatinib is an investigational small molecule being studied for the treatment of non-small-cell lung cancer. It is currently in Phase 1 clinical development as a combination therapy with amivantamab for unresectable metastatic non-small cell lung cancer. The drug is not yet approved and remains under investigation.
Capmatinib is a kinase inhibitor, belonging to the -tinib class of targeted therapies. It works by inhibiting kinase enzymes involved in cancer cell growth and survival. The drug is being evaluated in combination with amivantamab for the treatment of non-small-cell lung cancer.
Capmatinib is being developed by Johnson & Johnson, a company traded on the stock exchange under the ticker symbol JNJ. The company is currently conducting a Phase 1 clinical trial to evaluate the drug in combination with amivantamab for non-small-cell lung cancer.
Capmatinib is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 study is evaluating the safety and efficacy of capmatinib in combination with amivantamab for unresectable metastatic non-small cell lung cancer.
Capmatinib is being studied in clinical trial NCT05488314, titled "A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer." This Phase 1 trial is active but not recruiting, with an enrollment of 57 participants across multiple countries including the United States, Brazil, Canada, China, and European nations.
No, Capmatinib is not the same as amivantamab. Capmatinib is a small molecule kinase inhibitor, while amivantamab is a different drug. They are being studied together in combination therapy for non-small-cell lung cancer, but they are distinct investigational agents with different mechanisms of action.